A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)

10.1007/s10637-015-0313-8

Saved in:

Bibliographic Details
Main Authors:	Chiu, J.W, Hotte, S.J, Kollmannsberger, C.K, Renouf, D.J, Cescon, D.W, Hedley, D, Chow, S, Moscow, J, Chen, Z, Perry, M, Diaz-Padilla, I, Tan, D, Hirte, H, McWhirter, E, Chen, H, Siu, L.L, Bedard, P.L
Other Authors:	MEDICINE
Format:	Article
Published:	Springer New York LLC 2020
Subjects:	angiogenic factor angiopoietin receptor temsirolimus thymidine phosphorylase trebananib antineoplastic agent hybrid protein rapamycin adult advanced cancer aged anorexia antineoplastic activity Article blood level cancer fatigue clinical article clinical effectiveness controlled study drug efficacy drug mechanism drug response drug safety drug tolerability edema female human lymphocytopenia male maximum plasma concentration monocyte mucosa inflammation multiple cycle treatment nausea phase 1 clinical trial priority journal protein expression rash solid tumor analogs and derivatives chemically induced clinical trial fatigue maximum tolerated dose middle aged Neoplasms pathology treatment outcome Adult Aged Anorexia Antineoplastic Combined Chemotherapy Protocols Edema Fatigue Female Humans Male Maximum Tolerated Dose Middle Aged Recombinant Fusion Proteins Sirolimus Treatment Outcome
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/179600
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-179600
record_format	dspace
spelling	sg-nus-scholar.10635-1796002024-04-24T05:53:09Z A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041) Chiu, J.W Hotte, S.J Kollmannsberger, C.K Renouf, D.J Cescon, D.W Hedley, D Chow, S Moscow, J Chen, Z Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, L.L Bedard, P.L MEDICINE angiogenic factor angiopoietin receptor temsirolimus thymidine phosphorylase trebananib antineoplastic agent hybrid protein rapamycin temsirolimus trebananib adult advanced cancer aged anorexia antineoplastic activity Article blood level cancer fatigue clinical article clinical effectiveness controlled study drug efficacy drug mechanism drug response drug safety drug tolerability edema female human lymphocytopenia male maximum plasma concentration monocyte mucosa inflammation multiple cycle treatment nausea phase 1 clinical trial priority journal protein expression rash solid tumor analogs and derivatives anorexia chemically induced clinical trial edema fatigue maximum tolerated dose middle aged Neoplasms pathology treatment outcome Adult Aged Anorexia Antineoplastic Combined Chemotherapy Protocols Edema Fatigue Female Humans Male Maximum Tolerated Dose Middle Aged Neoplasms Recombinant Fusion Proteins Sirolimus Treatment Outcome 10.1007/s10637-015-0313-8 Investigational New Drugs 34 1 104-111 2020-10-23T07:59:53Z 2020-10-23T07:59:53Z 2016 Article Chiu, J.W, Hotte, S.J, Kollmannsberger, C.K, Renouf, D.J, Cescon, D.W, Hedley, D, Chow, S, Moscow, J, Chen, Z, Perry, M, Diaz-Padilla, I, Tan, D, Hirte, H, McWhirter, E, Chen, H, Siu, L.L, Bedard, P.L (2016). A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041). Investigational New Drugs 34 (1) : 104-111. ScholarBank@NUS Repository. https://doi.org/10.1007/s10637-015-0313-8 0167-6997 https://scholarbank.nus.edu.sg/handle/10635/179600 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Springer New York LLC Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	angiogenic factor angiopoietin receptor temsirolimus thymidine phosphorylase trebananib antineoplastic agent hybrid protein rapamycin temsirolimus trebananib adult advanced cancer aged anorexia antineoplastic activity Article blood level cancer fatigue clinical article clinical effectiveness controlled study drug efficacy drug mechanism drug response drug safety drug tolerability edema female human lymphocytopenia male maximum plasma concentration monocyte mucosa inflammation multiple cycle treatment nausea phase 1 clinical trial priority journal protein expression rash solid tumor analogs and derivatives anorexia chemically induced clinical trial edema fatigue maximum tolerated dose middle aged Neoplasms pathology treatment outcome Adult Aged Anorexia Antineoplastic Combined Chemotherapy Protocols Edema Fatigue Female Humans Male Maximum Tolerated Dose Middle Aged Neoplasms Recombinant Fusion Proteins Sirolimus Treatment Outcome
spellingShingle	angiogenic factor angiopoietin receptor temsirolimus thymidine phosphorylase trebananib antineoplastic agent hybrid protein rapamycin temsirolimus trebananib adult advanced cancer aged anorexia antineoplastic activity Article blood level cancer fatigue clinical article clinical effectiveness controlled study drug efficacy drug mechanism drug response drug safety drug tolerability edema female human lymphocytopenia male maximum plasma concentration monocyte mucosa inflammation multiple cycle treatment nausea phase 1 clinical trial priority journal protein expression rash solid tumor analogs and derivatives anorexia chemically induced clinical trial edema fatigue maximum tolerated dose middle aged Neoplasms pathology treatment outcome Adult Aged Anorexia Antineoplastic Combined Chemotherapy Protocols Edema Fatigue Female Humans Male Maximum Tolerated Dose Middle Aged Neoplasms Recombinant Fusion Proteins Sirolimus Treatment Outcome Chiu, J.W Hotte, S.J Kollmannsberger, C.K Renouf, D.J Cescon, D.W Hedley, D Chow, S Moscow, J Chen, Z Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, L.L Bedard, P.L A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
description	10.1007/s10637-015-0313-8
author2	MEDICINE
author_facet	MEDICINE Chiu, J.W Hotte, S.J Kollmannsberger, C.K Renouf, D.J Cescon, D.W Hedley, D Chow, S Moscow, J Chen, Z Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, L.L Bedard, P.L
format	Article
author	Chiu, J.W Hotte, S.J Kollmannsberger, C.K Renouf, D.J Cescon, D.W Hedley, D Chow, S Moscow, J Chen, Z Perry, M Diaz-Padilla, I Tan, D Hirte, H McWhirter, E Chen, H Siu, L.L Bedard, P.L
author_sort	Chiu, J.W
title	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
title_short	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
title_full	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
title_fullStr	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
title_full_unstemmed	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)
title_sort	phase i trial of ang1/2-tie2 inhibitor trebaninib (amg386) and temsirolimus in advanced solid tumors (pjc008/nci#9041)
publisher	Springer New York LLC
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/179600
_version_	1800914560581894144

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)

Similar Items